Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome

Pediatrics

Volumn 135, Issue 6, 2015, Pages e1506-e1509

  Cullinan, Noelle ^a   Gorman, Kathleen Mary ^a   Riordan, Michael ^a   Waldron, Mary ^a   Goodship, Timothy H J ^b   Awan, Atif ^a  

^a CHILDREN S UNIVERSITY HOSPITAL   (Ireland)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFTRIAXONE; CREATININE; ECULIZUMAB; HEMOGLOBIN; LACTATE DEHYDROGENASE; PENICILLIN DERIVATIVE; MONOCLONAL ANTIBODY;

ANTIBIOTIC SENSITIVITY; ARTICLE; BRONCHIOLITIS; CASE REPORT; DISEASE ASSOCIATION; ELECTROLYTE DISTURBANCE; ERYTHROCYTE FRAGILITY; FEMALE; FEVER; GENE DELETION; GESTATIONAL AGE; HEMATURIA; HEMODIALYSIS; HEPATOMEGALY; HUMAN; HYPOCALCEMIA; HYPOTENSION; INFANT; KIDNEY BIOPSY; KIDNEY FUNCTION; MENINGOCOCCEMIA; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA MENINGITIDIS; NEUTROPHILIA; PERITONEAL DIALYSIS; PLASMAPHERESIS; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; RASH; RELAPSE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; VACCINATION; VEIN DISEASE; VIRUS INFECTION; ATYPICAL HEMOLYTIC UREMIC SYNDROME; TIME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; FEMALE; HUMANS; INFANT; TIME FACTORS;

EID: 84930607950     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-3503     Document Type: Article

References (17)

1. Johnson S, Stojanovic J, Ariceta G, et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol. 2014;29(10):1967-1978
2. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-562
3. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844-1859
4. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60
5. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33(6):508-530
6. Francis NJ, McNicholas B, Awan A, et al. A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood. 2012;119(2):591-601
7. Ariceta G, Besbas N, Johnson S, et al; European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009;24(4):687-696
8. Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol. 2013;56(3):199-212
9. Nürnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome [published correction appears in N Engl J Med. 2009;360(23):2487]. N Engl J Med. 2009;360(5):542-544
10. Kelly RJ, Hill A, Arnold LM, et al. Longterm treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786-6792
11. Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol. 2011;26(11):2085-2088
12. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical hemolytic uremic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8(11):643-657
13. Lapeyraque A-L, Frémeaux-Bacchi V, Robitaille P. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011;26(4):621-624
14. Vilalta R, Lara E, Madrid A, et al. Longterm eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol. 2012;27(12):2323-2326
15. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-2181
16. Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. 2013;3(11):e003573
17. Struijk GH, Bouts AH, Rijkers GT, Kuin EA, ten Berge IJ, Bemelman FJ. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant. 2013;13(3):819-820